Evidence map›Paper›PMID 27203582›Full record

ArticlePLoS genetics2016

N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.

Xudong Liu, Chuan-En Wang, Yan Hong, Ting Zhao, Guohao Wang, Marta A Gaertig, Miao Sun, Shihua Li, Xiao-Jiang Li

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Insights into RNA-mediated pathology in new mouse models of Huntington's disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Xudong LiuState Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China.
Chuan-En WangDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Yan HongDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Ting ZhaoDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Guohao WangState Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China.
Marta A GaertigDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Miao SunDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Shihua LiDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Xiao-Jiang LiState Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China.
Emory University · USInstitute of Genetics and Developmental Biology · CNChinese Academy of Sciences · CN

Funding

Neuronal function of huntingtin-associated proteinR01NS036232 · NINDS · EMORY UNIVERSITY · PI ESCAYG, ANDREW P · 1998 to 2021
$6.7M
Nuclear Toxicity of Huntington Disease ProteinR01NS041669 · NINDS · EMORY UNIVERSITY · PI LI, XIAO-JIANG · 2001 to 2015
$4.6M
Synaptic toxicity of Huntington disease proteinR01AG019206 · NIA · EMORY UNIVERSITY · PI LI, XIAO-JIANG · 2001 to 2016
$4.5M
Glial huntingtin and neurodegenerationR01NS095181 · NINDS · EMORY UNIVERSITY · PI WEINSHENKER, DAVID · 2015 to 2019
$1.7M
Polyglutamine Expansion Length Dependent PathologyR01NS095279 · NINDS · EMORY UNIVERSITY · PI WARREN, STEPHEN T. · 2015 to 2019
$1.7M
Synaptic accumulation of misfolded proteins and neurodegenerationR56AG019206 · NIA · EMORY UNIVERSITY · PI JIN, PENG · 2018 to 2018
$489k
NIA NIH HHS R01 AG019206NIA NIH HHS R56 AG019206NINDS NIH HHS R01 NS036232NINDS NIH HHS R01 NS041669NINDS NIH HHS R01 NS095181NINDS NIH HHS R01 NS095279
6 · The paper itself

Abstract

The Huntington's disease (HD) protein, huntingtin (HTT), is a large protein consisting of 3144 amino acids and has conserved N-terminal sequences that are followed by a polyglutamine (polyQ) repeat. Loss of Htt is known to cause embryonic lethality in mice, whereas polyQ expansion leads to adult neuronal degeneration. Whether N-terminal HTT is essential for neuronal development or contributes only to late-onset neurodegeneration remains unknown. We established HTT knock-in mice (N160Q-KI) expressing the first 208 amino acids of HTT with 160Q, and they show age-dependent HTT aggregates in the brain and neurological phenotypes. Importantly, the N-terminal mutant HTT also preferentially accumulates in the striatum, the brain region most affected in HD, indicating the importance of N-terminal HTT in selective neuropathology. That said, homozygous N160Q-KI mice are also embryonic lethal, suggesting that N-terminal HTT alone is unable to support embryonic development. Using Htt knockout neurons, we found that loss of Htt selectively affects the survival of developing neuronal cells, but not astrocytes, in culture. This neuronal degeneration could be rescued by a truncated HTT lacking the first 237 amino acids, but not by N-terminal HTT (1-208 amino acids). Also, the rescue effect depends on the region in HTT known to be involved in intracellular trafficking. Thus, the N-terminal HTT region may not be essential for the survival of developing neurons, but when carrying a large polyQ repeat, can cause selective neuropathology. These findings imply a possible therapeutic benefit of removing the N-terminal region of HTT containing the polyQ repeat to treat the neurodegeneration in HD.

Indexed as

AnimalsCorpus StriatumGene Knock-In TechniquesHumansHuntingtin ProteinHuntington DiseaseMiceMutationNerve DegenerationNerve Tissue ProteinsNeuronsPeptidesPhenotypeHtt protein, mouseHuntingtin ProteinNerve Tissue ProteinsPeptidespolyglutamine

Identifiers

PMID27203582
PMCPMC4874551
OpenAlexW2399750310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.